Columbus Macro LLC Has $2.32 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Columbus Macro LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 55.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,103 shares of the biopharmaceutical company’s stock after buying an additional 9,004 shares during the quarter. Columbus Macro LLC’s holdings in Gilead Sciences were worth $2,319,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC increased its holdings in shares of Gilead Sciences by 79.4% during the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares during the period. Wellington Management Group LLP grew its holdings in shares of Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Gilead Sciences by 723.3% during the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock valued at $594,370,000 after purchasing an additional 5,653,075 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Gilead Sciences by 350.1% in the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after purchasing an additional 1,793,145 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its position in Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after purchasing an additional 1,622,806 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 598,414 shares of company stock valued at $55,953,200. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 1.2 %

GILD stock opened at $98.38 on Tuesday. The business’s 50-day moving average is $92.42 and its 200 day moving average is $85.96. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $99.45. The stock has a market cap of $122.61 billion, a price-to-earnings ratio of 1,093.11, a PEG ratio of 1.37 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the business earned $2.29 earnings per share. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on GILD shares. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. BMO Capital Markets boosted their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $87.00 to $113.00 in a research report on Friday, January 10th. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Finally, Citigroup assumed coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price on the stock. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.